12 Best Twist Bioscience Alternatives & Competitors (2026)

AbCellera is a leading antibody discovery company using single-cell screening and AI to identify binders from immune repertoires at high speed. It excels in rapid hit identification for traditional targets and has supported multiple clinical programs through partnerships. Unlike Abalone Bio's focus on functional activation of GPCRs via massive parallel activity assays and survival-linked yeast, AbCellera prioritizes binding affinity and structural characterization with smaller functional follow-up. Its platform suits high-throughput discovery but lacks Abalone Bio's 100M-scale activity datasets for training AI on activators, making it less ideal for hard-to-drug GPCR modulation where precise function is required over inhibition.

AbCellera is a leading antibody discovery company using single-cell screening and AI to identify binders from immune repertoires at high speed. It excels in rapid hit identification for traditional targets and has supported multiple clinical programs through partnerships. Unlike Abalone Bio's focus on functional activation of GPCRs via massive parallel activity assays and survival-linked yeast, AbCellera prioritizes binding affinity and structural characterization with smaller functional follow-up. Its platform suits high-throughput discovery but lacks Abalone Bio's 100M-scale activity datasets for training AI on activators, making it less ideal for hard-to-drug GPCR modulation where precise function is required over inhibition.

IDT provides custom oligos and genes via chemical synthesis with fast online ordering and academic pricing. It is widely used for standard molecular biology needs. Versus Ansa, IDT offers quicker access for shorter sequences but may require more post-processing for very long or complex DNA compared to enzymatic methods.

Adimab offers yeast-based antibody discovery and optimization services emphasizing high-affinity binders and engineering for pharma partners. It leverages display technologies for rapid affinity maturation across diverse targets. Compared to Abalone Bio, Adimab centers on binding and developability rather than direct functional activity screening at 100M scale. Its yeast platform shares some similarities but does not link survival to GPCR activation or generate activity datasets for AI design of agonists. Abalone Bio's FAST approach provides an edge for activating challenging receptors where Adimab's methods may require extensive secondary assays.

GenScript delivers gene synthesis, protein services and custom DNA with global labs and competitive turnaround. Strengths include one-stop biotech services. In comparison to Ansa Biotechnologies, GenScript uses traditional methods that can be more accessible for routine orders but less optimized for ultra-long enzymatic DNA production.

Absci combines AI with synthetic biology for de novo antibody and protein design, screening libraries in high-throughput cellular assays. It targets broad biologics applications including some GPCR-related work. While Absci integrates AI heavily, it relies more on generative models from binding or expression data than Abalone Bio's proprietary functional activity measurements from 100 million antibodies. Abalone Bio's yeast survival linkage directly ties to GPCR modulation, offering stronger specificity for activators. Absci may suit general design needs but trails in scale of real functional GPCR data for side-effect-reduced therapies.

Eurofins Genomics supplies DNA sequencing and synthesis services with strong European presence and volume capabilities. It suits large-scale projects. Relative to Ansa, it relies on established chemical processes offering reliable but potentially less innovative long-strand synthesis options.

Codex DNA focuses on automated benchtop gene synthesis systems for synthetic biology labs. It enables on-site production. Compared to Ansa Biotechnologies enzymatic platform, Codex provides hardware solutions that may reduce outsourcing but with different throughput and length capabilities.

Thermo Fisher offers GeneArt synthesis services alongside broad life science tools. It is convenient for integrated lab workflows. Against Ansa, it provides chemical synthesis with extensive support infrastructure but may not match specialized enzymatic advantages for complex DNA.

Genmab develops differentiated antibody therapeutics using proprietary platforms like DuoBody for multispecifics, with a focus on oncology and autoimmune diseases. It has approved products emphasizing effector function and targeting. Unlike Abalone Bio's emphasis on GPCR activation via high-scale functional screening, Genmab prioritizes established antibody formats for inhibition or depletion. Its clinical success highlights specificity advantages but lacks Abalone Bio's yeast-based activity measurement or AI for hard-to-drug activators, positioning it better for validated targets than novel GPCR therapies.

ATUM specializes in DNA design and synthesis with AI-driven sequence optimization. It targets protein expression projects. In contrast to Ansa Biotechnologies, ATUM emphasizes design tools paired with synthesis that can complement or compete depending on project scale and length needs.